The goal of the Take Aim Initiative is to ensure that ALL patients diagnosed with non-small cell lung cancer (NSCLC) have access to high quality, comprehensive biomarker testing at diagnosis, progression, and recurrence to inform their decision making.
Thanks to the identification of new biomarkers and improved testing methods to detect known biomarkers, there are many treatment options, including clinical trials, now available to lung cancer patients. Despite this, many patients are still not being tested. Access to high quality, timely comprehensive biomarker testing is instrumental for patient access to the right treatment for them, leading to improved outcomes and better quality of life.
LUNGevity’s Take Aim Initiative launched in 2015 and is a multi-stakeholder, multi-year initiative to break down barriers to comprehensive biomarker testing. Since then, LUNGevity has collaborated with stakeholders including biotech, pharmaceutical, diagnostic industries, professional societies, and patient advocacy groups to address major challenges for patients accessing biomarker testing.
Take Aim works to address the following issues:
If you are interested in learning more about or partnering with LUNGevity on the Take Aim Initiative, please reach out to Nikki Martin, Director of Precision Medicine Initiatives, at [email protected].